drugset
drugset / Trial / NCT02828046

An Ascending Dose Study to Evaluate M281 Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)

NCT02828046 ↗

Phase 1 Completed 50 enrolled Momenta Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this study is to evaluate safety, tolerability, and PK/PD of M281 after single and multiple doses in healthy volunteers.

Timeline

Start
2016-05-09
Primary completion
2017-08-08
Completion
2017-08-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Nipocalimab Monoclonal antibody — —

Indications

No indication recorded.